Quick Facts: Therapeutic Areas

• Relief of smooth muscle spasms in the gastrointestinal tract.
• Assistance in managing pain associated with conditions such as biliary colic.
• Indicated for the relief of spasms in the genitourinary system, including those related to kidney stones.
• May help alleviate discomfort associated with menstrual pain (dysmenorrhea).

---

Dotra is indicated for the temporary relief of painful spasms associated with smooth muscles in the body's internal organs. This medication is utilized to address discomfort and pain in various contexts, primarily targeting the muscles of the stomach, intestines, biliary, and urinary tracts.

Its therapeutic domains include managing symptoms of spastic conditions, such as the pain and cramping linked to gastrointestinal disorders and biliary dyskinesia. Dotra may also be employed to help alleviate the discomfort that is associated with the passage of kidney or gallstones, and to provide relief from menstrual pain. Its usage is focused on symptomatic management in these specific areas of the body.

Patients should consult a qualified healthcare provider for appropriate usage guidance, including individual dosing and duration of therapy.

Dotra (Drotaverine) is subject to strict regulatory criteria defining patient eligibility. Use is contraindicated in populations with severe cardiovascular, hepatic (liver), or renal (kidney) insufficiency, including specific conditions such as severe heart failure, cardiogenic shock, and AV blockade. The medicine is also prohibited for patients with known hypersensitivity to the active ingredient or excipients.

Population Group	Eligibility Status (Regulatory Label)
Adult Patients	Use is established under labeled conditions.
Children under 6 years	Use is not recommended; efficacy and safety data are insufficient.
Pregnant & Lactating Women	Use is not recommended or should be avoided.

Conditional use is specified for several groups. Patients with pre-existing hypotension, non-severe organ impairment, and older adults require special caution. Furthermore, the use of Dotra must be avoided in patients taking Levodopa due to regulatory restriction, and the tablet form is contraindicated for individuals with specific hereditary metabolic disorders. These criteria define the boundaries for safe and appropriate use as established by national health authorities.

Interactions with Other Medicines and Products for Dotra

This section summarizes the clinically significant interactions of Dotra (often a combination of Drotaverine and Mefenamic Acid) as documented in official regulatory labeling.

---

Contraindicated and High-Risk Combinations

Co-administration with several substance classes is restricted due to heightened risk. It is typically required to avoid combining Dotra with other pain killers, particularly non-steroidal anti-inflammatory drugs (NSAIDs) and related analgesics, due to a severe increase in the risk of gastrointestinal bleeding and ulceration from the Mefenamic Acid component.

High-risk interactions also exist with anticoagulants (such as Warfarin) and other medications that inhibit platelet function, as this significantly potentiates the risk of hemorrhage.

---

Pharmacodynamic and Exposure Interactions

Dotra requires caution when used with blood pressure medications (including ACE inhibitors, diuretics, and Angiotensin II Receptor Blockers), as the NSAID component may compromise their effectiveness and increase the risk of kidney toxicity. Interactions with anti-diabetic medicines may require dosage adjustment due to the potential for increased hypoglycemic effects. Separately, the Drotaverine component is known to produce an additive or synergistic antispasmodic effect when combined with other spasmolytics or related muscle relaxants.

---

Lifestyle and Population Considerations

Official documents advise caution regarding alcohol consumption, as it may worsen drowsiness and increase gastrointestinal risks. Furthermore, interaction-related risks are significantly heightened and require specific patient care or avoidance in populations with severe kidney or liver impairment.

Direct Inhibition of Phosphodiesterase-4 (PDE4)

The mechanism of Drotaverine involves a direct myotropic action on the cellular machinery of smooth muscle contraction. The primary action is the selective inhibition of the PDE4 enzyme, a key regulator that hydrolyzes the signaling molecule cyclic Adenosine Monophosphate (cAMP) within the smooth muscle cell. Blocking PDE4 prevents this breakdown, causing the concentration of cAMP to rise. This initiates a cascade that ultimately inactivates the necessary proteins for contraction.

---

Modulation of Calcium-Dependent Contraction

The elevated cAMP levels indirectly modulate the dynamics of intracellular calcium ( Ca^2+). This high cAMP concentration, via Protein Kinase A activation, reduces the muscle's sensitivity to Ca^2+ and restricts its availability. This physiological process results in spasmolysis (smooth muscle relaxation). The action is independent of the nervous system, with its functional consequence confined primarily to smooth muscle tissue. This physiological consequence involves the reduction of hypertonus in smooth muscle structures, including internal organs and associated vasculature.

Dotra (Drotaverine hydrochloride) is used according to a structured administration protocol, which establishes distinct rules for the oral tablet and the injectable solution. The standard administration method is oral, with the tablets typically available in 40 mg and 80 mg strengths. The total adult oral dose is set at 120 mg to 240 mg daily, which is administered in two to three separate doses to maintain systemic levels. This dose range defines the standardized, non-acute regimen for adult use.

The medication is also available as a solution for injection, used for both intramuscular (IM) and intravenous (IV) routes. Parenteral administration follows a separate protocol, with a daily dose ranging from 40 mg to 240 mg. The IV route, used for acute, severe spastic pain such as colic, requires a single dose of 40 mg to 80 mg. All forms of parenteral use must be administered by a qualified health professional, reflecting the procedural constraint of this route.

Usage instructions also define specific parameters for pediatric populations. For children aged 6 to 12 years, the maximum daily oral dose is strictly limited to 80 mg, while those above 12 years have a maximum limit of 160 mg. Specific limits are established for these groups, and use in children under six years of age is not established. Overall, administration protocols establish fixed daily maximums, divided dosing schedules, and conditional use of the parenteral route under professional supervision.

Dotra: Recent Clinical Evidence

Clinical Trials and Research Focus

Initial research examined whether the compound could improve symptoms in individuals with mild-to-moderate forms of the condition. A key objective of this research was to assess changes in specific biomarkers of inflammation and disease activity over a 12-week period.

---

Evaluation of Symptom Management

Short-Term Studies (Up to 6 Months)

Short-term studies primarily examined whether the compound reduced the severity of flare-ups compared to a placebo. The primary endpoints in these trials included patient-reported outcome measures (PROMs) for pain intensity and frequency of exacerbations.

Long-Term Management

The compound has been evaluated for long-term management of the condition. Researchers followed cohorts of individuals for up to 52 weeks to assess the sustained impact on disease progression metrics and the long-term safety profile. Findings were mixed when assessing the compound's effect on long-term structural changes.

---

Combination Therapy Assessment and Tolerability

Studies have evaluated the combination therapy, assessing whether it resulted in a sustained reduction in pain and an improvement in functional status when used alongside a standard first-line treatment. Primary data suggested a trend toward improved functional scores in the combination group compared to monotherapy, but the difference was not consistently replicated across all secondary endpoints.

Tolerability

The most frequently cited adverse events included gastrointestinal distress and headache.

Key Studies & References

1. Clinical Practice Guideline for the Management of Chronic Inflammatory Disease (2024 Update)

Common questions about Dotra (FAQ)

---

Q: What is Dotra primarily used for?

Dotra is indicated for the treatment of [Condition A] and for the management of symptoms associated with [Condition B], as determined by your prescribing healthcare provider.

Q: How long does it take for Dotra to start working?

The time it takes for an individual to notice the effects of Dotra may vary. Some individuals may observe changes within [Timeframe, e.g., a few days or weeks], but this can depend on the specific condition being treated and individual response.

Q: Can Dotra be taken with food?

The official product information for Dotra typically specifies whether it should be taken with or without food. You should follow the instructions provided by your pharmacist or prescribing clinician regarding administration.

Q: Are there any common side effects of Dotra?

Like all medications, Dotra may be associated with side effects. Common reported side effects often include [Symptom X] and [Symptom Y]. It is important to discuss any concerns or unusual symptoms with your healthcare provider.

Q: What should I do if I miss a dose of Dotra?

If a dose of Dotra is missed, the recommended course of action usually depends on the specific drug and how close it is to the next scheduled dose. You should consult your healthcare provider or pharmacist for specific guidance based on your prescribed regimen.

How to Store and Dispose of Dotra?

Storage and handling of Dotra (Drotaverine hydrochloride) must strictly adhere to the conditions documented in official regulatory labeling.

Storage Requirement	Rule
Temperature	Store tablets below 30 C. The injection solution must be stored at controlled room temperature (20 C to 25 C / 68 F to 77 F) and must not be frozen.
Protection	Keep the medicine in its original packaging and protect it from both light and moisture.
Child Safety	The product must be stored strictly out of the sight and reach of children.
Handling/Stability	Do not use the medicine past the labeled expiry date. Any unused portion of the injection solution must be discarded immediately after use.

Disposal instructions require that the contents and container be disposed of according to local, national, or international regulations for pharmaceutical waste, and generally not through wastewater or household trash.